Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| PharmaTher Holdings Ltd | KETABET | Depression | Phase 2 | Intravenous | Psychiatric | |
| PharmaTher Holdings Ltd | KETARX (ketamine) | Rett syndrome | Phase 2 | Ongoing | intravenous intramuscular | Genetic Disorder |
| Pharming Group N.V. | Leniolisib | Common variable immunodeficiency (CVID) | Phase 2 | Enrollment Initiation | Oral | Immunology |
| Pharming Group N.V. | Leniolisib | PID disorders with immune dysregulation | Phase 2 | Enrollment Initiation | Oral | Immunology |
| Pharvaris N.V. | PHVS416 - (RAPIDe-3) | Hereditary angioedema - on demand | NDA Filing | Data Released | Oral | Immunology |
| Pharvaris N.V. | Deucrictibant (PHVS416) - (CHAPTER-3) | Hereditary angioedema - prophylactic use | Phase 3 | Trial Planned | Oral | Immunology |
| Pharvaris N.V. | Deucrictibant (PHA121) - (CREAATE) | Hereditary angioedema | Phase 3 | Ongoing | Oral | Genetic Disorder |
| Pharvaris N.V. | Deucrictibant extended-release tablet - (CHAPTER-4) | HAE attacks | Phase 3 | Ongoing | Oral | Genetic Disorder |
